Scorpion Capital shorts drug developer Soleno

Soleno Therapeutics

15/08/2025 14:15

Aug 15 (Reuters) - Scorpion Capital disclosed a short position in Soleno Therapeutics SLNO.O on Friday, citing issues with the drug developer's recently approved treatment Vykat XR.

Shares of Soleno declined 15% in premarket trading. The company did not immediately respond to a Reuters request for comment.

 (Reporting by Bhanvi Satija and Sneha S K in Bengaluru; Editing by Shilpi Majumdar)

 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))